| Journal | CNS neuroscience & therapeutics |
| Study Type | Clinical Study |
| Population | Human participants |
This item covers developments relevant to cannabis medicine and clinical practice. Clinicians monitoring evidence in this area should review the source material.
Childhood absence epilepsy (CAE) arises from dysfunctional corticothalamic networks generating spike wave discharges (SWDs) and behavioral arrest. Despite available treatments, a significant proportion of patients remain pharmacoresistant and develop neuropsychiatric comorbidities. The endocannabinoid system (ECS), through activity-dependent signaling, is a key regulator of synaptic and network stability, but its therapeutic potential in absence epilepsy remains unresolved. To determine whether selective elevation of endogenous cannabinoid tone-particularly anandamide (AEA)-via inhibition of fatty acid amide hydrolase (FAAH) suppresses absence seizures and to define the contribution of thalamic mechanisms. Video-EEG recordings were performed in Genetic Absence Epilepsy Rats from Strasbourg (GAERS), combining automated detection and blinded validation of SWDs. The irreversible FAAH inhibitor PF-04457845 was administered acutely and subchronically and also delivered via bilateral microin
“This is a development worth tracking. The clinical implications will become clearer as more evidence accumulates.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
This study item was assembled from normalized source metadata and pipeline scoring.